Table 2.

Patient details and measurements of glucose, insulin, C-peptide, and NEFA

Placebo Group (n = 6) GH Group (n = 6)
0 mo 2 mo 0 mo 2 mo
Age, yr 44.2 ± 3.349.3 ± 1.8
Height, cm 168.6 ± 2.4170.6 ± 4.0
Weight, kg 79.7 ± 4.080.5 ± 4.4 76.8 ± 7.5 78.6 ± 7.7*
BMI, kg/m2 28.1 ± 1.528.4 ± 1.6 26.1 ± 1.7 26.7 ± 1.7
LBM, kg 45.0 ± 2.6 47.1 ± 3.048.0 ± 5.6 51.7 ± 6.3*
FFM, kg34.2 ± 1.8 33.9 ± 2.3 28.8 ± 4.527.0 ± 5.1
IGF-I, nmol/l 16.2 ± 2.014.6 ± 1.9 18.1 ± 2.7 42.7 ± 5.5
Glucose, mmol/l 4.85 ± 0.11 4.93 ± 0.095.18 ± 0.17 5.27 ± 0.09
Postprandial glucose AUC, mmol ⋅ l−1 ⋅ min1,544 ± 79 1,563 ± 42 1,474 ± 771,540 ± 55
Insulin, pmol/l 8.35 ± 1.5511.30 ± 1.32 12.75 ± 5.7421.65 ± 8.68
Postprandial insulin AUC, μmol ⋅ l−1 ⋅ min100 ± 25 89 ± 15 155 ± 60281 ± 141
C-peptide, nmol/l 0.40 ± 0.120.43 ± 0.13 0.23 ± 0.060.46 ± 0.07*
Postprandial C-peptide AUC, nmol ⋅ l−1 ⋅ min456 ± 67 420 ± 52 266 ± 33321 ± 42
NEFA, mmol/l 0.57 ± 0.040.58 ± 0.04 0.47 ± 0.060.63 ± 0.04*
  • Values are means ± SE; n, no. of patients. NEFA, nonesterified fatty acids; BMI, body mass index; LBM, lean body mass; FFM, fat-free mass; IGF-I, insulin-like growth factor I; AUC, area under curve.

  • * Significantly different from 0 mo (P < 0.05).

  • Significantly different from 0 mo (P < 0.005).